The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis.
Open accessAbstract
Two monoclonal antibodies (mAbs) against bovine heparin-binding growth factor II (HBGF-II)/basic fibroblast growth factor (bFGF) were obtained from mouse hybridoma cell lines. They were highly specific for bFGF from bovine, human, and mouse sources and did not cross-react with bovine heparin-binding growth factor I (HBGF-I)/acidic fibroblast growth factor (aFGF). The immunoglobulin class and subclass of these mAbs were IgG1, K. The apparent dissociation constant (Kd) for bFGF of these mAbs ranged from 10(-9) to 10(-10) M. One mAb (bFM-2) also cross-reacted with heat-inactivated bFGF, while the other mAb (bFM-1) did not, suggesting that bFM-1 recognized the conformation of the bFGF molecule necessary for its biological activity. These mAbs inhibited growth of cultured bovine capillary endothelial cells in both the presence and absence of exogenous bFGF, indicating the autocrine action of this growth factor in in vitro growth of these cells. On the other hand, injection of these hybridoma cell lines s.c. into the backs of athymic mice resulted in development of highly vascularized solid tumors and a sustained high level of anti-bFGF activity in the blood of the tumor-bearing mice. These findings suggest that bFGF is not essential as an autocrine or paracrine growth factor for angiogenesis in vivo. These mAbs should be useful in further studies on the physiological role and the conformation-function relationship of bFGF because they block its biological activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heparin protects basic and acidic FGF from inactivation
Gospodarowicz, D., & Cheng, J. (1986) · Journal of Cellular Physiology · doi:10.1002/jcp.1041280317 · Cited by 853
Cited by
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
The Fgf Family of Growth Factors and Oncogenes
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60305-x · Cited by 1,145
Tropepe, V., Sibilia, M., Ciruna, B. G., Rossant, J., Wagner, E. F., & van der Kooy, D. (1999) · Developmental Biology · doi:10.1006/dbio.1998.9192 · Cited by 815
Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., Glass, M. C., Taub, D. T., Iannettoni, M. D., Whyte, R. I., & Strieter, R. M. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.981 · Cited by 353
Macrophage-derived angiogenesis factors
Sunderkötter, C., Goebeler, M., Schulze-Osthoff, K., Bhardwaj, R., & Sorg, C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90077-y · Cited by 332
Bremnes, R. M., Camps, C., & Sirera, R. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.09.005 · Cited by 330
Angiogenesis inhibition: A review
Auerbach, W., & Auerbach, R. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90027-2 · Cited by 321
Physical exercise induces FGF-2 and its mRNA in the hippocampus
Gómez-Pinilla, F., Dao, L., & So, V. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00375-2 · Cited by 292
Risau, W. (1990) · Progress in Growth Factor Research · doi:10.1016/0955-2235(90)90010-h · Cited by 145
Metadata
- Authors
- Matsuzaki, K., Yoshitake, Y., Matuo, Y., Sasaki, H., & Nishikawa, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1989-12
- Volume
- 86
- Issue
- 24
- Pages
- 9911-9915
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2056440007
- Cited by
- 164
- References
- 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.